has extended an agreement to market BioGenex
’ Xmatrx® platform for the automation
of its FISH
product line. Under the terms of the agreement, BioGenex will receive a multiyear minimum volume commitment from Abbott.
The original technology co-development and distribution agreement and this extension give Abbott customers will have the option to run IHC and FISH on the Xmatrx, and BioGenex customers to run FISH on their system. The Xmatrx will be co-branded and marketed, and both parties to collaborate in aiding adoption of FISH, IHC, and ISH as primary tools in molecular diagnostics and personalized medicine.
The Xmatrx platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pre-treatment to final cover-slipping, according to BioGenex. It is designed for optimal results with Abbott Molecular AutoFISH™ reagents and FISH technology.